메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 -- ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 uses proprietary deep learning algorithms to automatically identify abnorm
- 김갑성 기자
- 2025-08-21 20:00
SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health

Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company held an exclusive meeting with the Gates Foundation in line with the visit of Bill Gates, Founder and Chair of the Foundation, to Korea to discuss ways to advance global health collaboration.&nbs
- 김갑성 기자
- 2025-08-21 20:00
BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization

Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of antibody/XDC therapies via international GMP standards and commercial capabilities SUZHOU, China, Aug. 21, 2025 -- BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Control (BPOM). This mark
- 김갑성 기자
- 2025-08-21 20:00
FDA clearance of Salix® Coronary Plaque module

[ 메디채널 김갑성 기자 ] Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 -- Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the FDA) for Artrya's proprietary, Salix&r
- 김갑성 기자
- 2025-08-21 19:43
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results

Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET DURHAM, N.C., and BEIJING, Aug. 21, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK),
- 김갑성 기자
- 2025-08-21 18:02
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM

[ 메디채널 김갑성 기자 ] Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices. Now in
- 김갑성 기자
- 2025-08-21 17:38
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal

YONGIN, South Korea, Aug. 21, 2025 -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal. Hunter syndrome (MPS II) is a rare genetic disorder caused by mutations in the iduronate-2-s
- 김갑성 기자
- 2025-08-21 13:00
Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!

TAIPEI, Aug. 21, 2025 -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launch two new products. To explore WINMAP™ technology for vaccines and pharmaceuticals, join WCC at the Total Store Expo on August 23–25 in San Diego, CA: Booth # 900 Following a successful debut at BIO Asia in Taiwan (July 23–27), WCC will offer demonstrations of its new products at TSE, allowing attendees to witness the benefits of microneedle-based
- 김갑성 기자
- 2025-08-21 09:23
바이탈 머티리얼즈, 양자 플럭스 광자 계수 CT(PCCT) 완전 수직 통합 기술 공개

[ 메디채널 김갑성 기자 ] 베이징 2025년 8월 21일 -- 8월 15일부터 17일까지 베이징에서 제31회 중국 국제 의료장비 전시회 및 과학 콘퍼런스(China-Hospeq 2025)가 개최됐다. 바이탈 머티리얼즈(Vital Materials)는 중국이 자체적으로 개발한 광자 계수 CT(PCCT) 스캐너 VITA Genesis를 공식 출시하며, 글로벌 의료 영상 기술이 '양자 플럭스(Quantum Flux)' 감지 시대에 진입했음을 알렸다. 이번 출시는 중국의 정밀 진단 및 치료 혁신에 힘을 실었다. PCCT의 핵심 기술인 광자 계수 검출기(PCD)는 기존 에너지 통합 검출기(EID)와 상당한 차이가 있다. 기존 CT 스캐너는 X선 광자를 먼저 가시광선으로 변환한 뒤, 다시 전기 신호로 바꾸는 과정을 거친다. 반면 PCCT 검출기는 반도체 소재를 활용해 X선 광자가 전자를 활성화해 에너지에 비례하는 전자-정공 쌍을 형성한다. 이렇게 발생한 전하 운반체는 전기장에 의해 분리돼 전기 펄스를 만들어낸다. ASIC(애플리케이션별 집적 회로)는 이 펄스를 에너지 구간별로 분류해 정밀한 광자 계수와 에너지 분해능을 제공한다. 이러한
- 김갑성 기자
- 2025-08-21 08:52
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performance[2]: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%[3] and on track to meet full year guidance[4]. Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® m
- 김갑성 기자
- 2025-08-21 08:23

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 30일 17시 20분